Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
2.
Wakayama T, Maniwa Y, Ago H, Kakazu N, Abe T (2001) A variant form of myelodysplastic syndrome with Ph—minor-BCR/ABL transcript. Int J Hematol 74(1):58–63CrossRefPubMed
3.
Nowell PC, Hungerford DA (1960) A minute chromosome n human chronic granualocytic leukemia. Science 132:1497
4.
Paridar M, Ghalesardi OK, Seghatoleslami M, Ahmadzadeh A, Khosravi A, Saki N (2017) Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach. J Cancer Metastasis Treat 3:38–44CrossRef
5.
Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M (2004) Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia—retrospective study and review of literature. Leuk Res 28(6):579–586CrossRefPubMed
Metadata
Title
De Novo Philadelphia Chromosome (BCR/ABL1) Positive Myelodysplastic Syndrome: Is it a Distinct Molecular and Clinical Entity?
Author
Darko Katalinic
Publication date
01-04-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0857-1

Other articles of this Issue 2/2018

Indian Journal of Hematology and Blood Transfusion 2/2018 Go to the issue

Original Article

Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study

Original Article

Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation

Original Article

Utility of CD157 as a Common Leukocytes Marker for Paroxysmal Nocturnal Hemoglobinuria Screening in a Single Tube Five Color Combination

Images

Verrucous Skin Lesions in a Case of Acute Lymphoblastic Leukemia: A Rare Manifestation of Cytomegalovirus Infection

Letter to the Editor

CD38—Negative Myeloma with Anaplastic Morphology at Presentation: A Case Report

Correspondence

Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits